<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780713</url>
  </required_header>
  <id_info>
    <org_study_id>D6090C00005</org_study_id>
    <nct_id>NCT02780713</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects</brief_title>
  <acronym>PK</acronym>
  <official_title>A Phase I Study to Evaluate the Pharmacokinetic and Safety Profile of AZD9496 Following Single Dose Administration of Different Forms and Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 open label single centre study of AZD9496 administered orally in healthy&#xD;
      volunteers. The study design involves single administration of different forms, formulations&#xD;
      and doses of AZD9496. The study is designed to investigate these different AZD9496 variants.&#xD;
      The study will evaluate the pharmacokinetic profiles and the safety and tolerability of the&#xD;
      different forms, formulations and doses of AZD9496&#xD;
&#xD;
      This is a fixed sequence study with 5-sequential treatment periods in healthy volunteers.&#xD;
      Each volunteer will receive 5 single doses of AZD9496 in different forms, formulations and&#xD;
      doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 1, open-label, single centre study to assess the pharmacokinetics, Safety and&#xD;
      tolerability of different forms, formulations and doses of AZD9496 in healthy volunteers.&#xD;
      This is a fixed sequence study with 5-sequential treatment periods. Each subject will receive&#xD;
      5 single doses of AZD9496 in different forms, formulations and doses.&#xD;
&#xD;
        -  Treatment period one will assess AZD9496 Variant A: 100mg.&#xD;
&#xD;
        -  Treatment period two will assess AZD9496 Reference form: 100mg.&#xD;
&#xD;
        -  Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg.&#xD;
&#xD;
        -  Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.&#xD;
&#xD;
        -  Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: *300mg. *Based on a&#xD;
           review of pharmacokinetic and safety results from Treatment Periods 1, 3 and 4, a lower&#xD;
           dose of 200 mg may be administered in Treatment Period 5.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2016</start_date>
  <completion_date type="Actual">September 20, 2016</completion_date>
  <primary_completion_date type="Actual">September 20, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites at Each Treatment Period.</measure>
    <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
    <description>To evaluate maximum observed plasma concentration (Cmax) for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve From Time Zero to Time With Last Observation (AUC0-t) for AZD9496 and Its Metabolites at Each Treatment Period</measure>
    <time_frame>Regular Pharmacokinetic measurement: At Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
    <description>To evaluate the area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUC (0-t) of AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration (Cmax) for Variant A, B and C of AZD9496 Compared to the AZD9496 Reference</measure>
    <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
    <description>To evaluate maximum plasma concentration (Cmax) of capsule variants by comparing with reference AZD9496</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve From Time Zero to Time With Last Observation (AUC0-t) for Variant A, B and C of AZD9496 Compared to the AZD9496 Reference</measure>
    <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
    <description>To evaluate area under curve from time zero to time with last observation (AUC0-t) of variants by comparing with reference AZD9496</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve From Time Zero to Infinity for Variant A, B and C of AZD9496 Compared to the AZD9496 Reference</measure>
    <time_frame>Regular Pharmacokinnetic measurement Pre-dose, 0.5, 1, 1.5, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24, and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
    <description>To evaluate area under the curve from time zero to time infinity (AUC 0-infinity) of variants by comparing with reference AZD9496</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve From Time Zero to Infinity (AUC 0-infinity) for AZD9496 and Metabolites at Each Treatment Period</measure>
    <time_frame>Regular pharmacokinetic measurement pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
    <description>To evaluate area under the curve from time zero to infinity (AUC 0-infinity) for AZD9496 and its metabolites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for AZD9496 and Its Metabolites at Each Treatment Period.</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
    <description>To evaluate time to reach maximum observed plasma concentration (Tmax) for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Half-life ( t½,Eff) for AZD9496 and Its Metabolites at Each Treatment Period</measure>
    <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
    <description>To evaluate effective half-life (t½,eff), for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite to Parent Ratios (MRAUC0-t, MRCmax, MRAUC) at Each Treatment Period.</measure>
    <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
    <description>To evaluate metabolite to parent ratios (MRAUC0-t, MRCmax, MRAUC) at each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC From Time Zero to 12 and 24 Hours Post-dose for AZD9496 and Its Metabolites at Each Treatment Period</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: The Terminal Elimination Half-life (t½,λz) for AZD9496 and Its Metabolites at Each Treatment Period</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Apparent Volume of Distribution (Vss/F) of AZD9496 and Its Metabolites at Each Treatment Period</measure>
    <time_frame>Day 1, Day 2, Day 3 and Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Apparent Oral Clearance (CL/F) of AZD9496 and Its Metabolites at Each Treatment Period</measure>
    <time_frame>Day 1, Day 2, Day 3 and Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Apparent Terminal Elimination Rate Constant (λz) of AZD9496 and Its Metabolites at Each Treatment Period</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Mean Residence Time (MRT) of AZD9496 and Its Metabolites at Each Treatment Period</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AZD9496</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a fixed sequence study with 5-sequential treatment periods in healthy volunteers. Each volunteer will receive 5 single doses of AZD9496 in different forms, formulations and doses.&#xD;
Treatment period 1 will assess AZD9496 Variant A: 100mg.&#xD;
Treatment period 2 will assess AZD9496 Reference: 100mg.&#xD;
Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg.&#xD;
Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.&#xD;
Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: *300mg. *Based on a review of PK and safety results from Treatment Periods 1, 3 and 4, a lower dose of 200 mg may be administered in Treatment Period 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9496 (Reference)</intervention_name>
    <description>AZD9496 (Reference)</description>
    <arm_group_label>AZD9496</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9496 Variant A</intervention_name>
    <description>AZD9496 Variant A.</description>
    <arm_group_label>AZD9496</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9496 Variant B</intervention_name>
    <description>AZD9496 Variant B</description>
    <arm_group_label>AZD9496</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9496 Variant C</intervention_name>
    <description>AZD9496 Variant C</description>
    <arm_group_label>AZD9496</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9496 Variant D</intervention_name>
    <description>AZD9496 Variant D</description>
    <arm_group_label>AZD9496</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated, written informed consent prior to any study specific&#xD;
             procedures.&#xD;
&#xD;
          2. Healthy male and/or female subjects aged 18 to 65 years with suitable veins for&#xD;
             cannulation or repeated venipuncture.&#xD;
&#xD;
          3. Females must have a negative pregnancy test at screening and on admission to the unit,&#xD;
             must not be lactating and must be of non-childbearing potential, confirmed at&#xD;
             screening by fulfilling 1 of the following criteria: Post-menopausal defined as&#xD;
             amenorrhea for at least 12 months or more following cessation of all exogenous&#xD;
             hormonal treatments and FSH levels in the post-menopausal range (OR) Documentation of&#xD;
             irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or&#xD;
             bilateral salpingectomy, but not tubal ligation&#xD;
&#xD;
          4. Male subjects aged 18 to 39 years must be vasectomized. Male subjects aged 40 to 65&#xD;
             years must either be vasectomized or have no intention of fathering a child for a&#xD;
             period of 6 months after receiving the last dose of IMP.&#xD;
&#xD;
          5. Have a body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive, and weigh at&#xD;
             least 50 kg and no more than 100 kg, inclusive.&#xD;
&#xD;
          6. Values for AST, ALT, TBL, GGT and ALP must be at or below the upper limit of normal&#xD;
             ranges at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any clinically significant disease or disorder which, in the opinion of the&#xD;
             investigator, may either put the subject at risk because of participation in the&#xD;
             study, or influence the results or the subject's ability to participate in the study.&#xD;
&#xD;
          2. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other&#xD;
             condition known to interfere with absorption, distribution, metabolism, or excretion&#xD;
             of drugs.&#xD;
&#xD;
          3. Any clinically significant illness, medical/surgical procedure, or trauma within 4&#xD;
             weeks of the first administration of IMP.&#xD;
&#xD;
          4. Previous history of venous or arterial thromboembolism or thrombophilia.&#xD;
&#xD;
          5. History of endometrial polyps, endometrial cancer, atypical endometrial hyperplasia,&#xD;
             or other endometrial disorders unless subjects have undergone total hysterectomy and&#xD;
             there is no evidence of active disease (females only).&#xD;
&#xD;
          6. Any clinically significant abnormalities in clinical chemistry (other than Inclusion&#xD;
             no.6), hematology, or urinalysis results at screening, as judged by the investigator.&#xD;
&#xD;
          7. Any clinically significant abnormal findings in supine vital signs, after 10 minutes&#xD;
             of supine rest, at screening and/or admission to the unit, defined as: (a) Systolic&#xD;
             blood pressure &lt; 90 mmHg or ≥ 150 mmHg (b) Diastolic blood pressure &lt; 50 mmHg or ≥ 95&#xD;
             mmHg and (c) Heart rate &lt; 45 or &gt; 90 beats per minute&#xD;
&#xD;
          8. Any clinically important abnormalities in rhythm, conduction or morphology of the&#xD;
             resting 12-lead ECG that, as judged by the investigator, that may interfere with the&#xD;
             interpretation of QTc interval changes, including abnormal ST-T-wave morphology or&#xD;
             pronounced left ventricular hypertrophy.&#xD;
&#xD;
          9. Prolonged QTcF &gt; 460 ms for females and QTcF &gt; 450 ms for males or family history of&#xD;
             long QT syndrome.&#xD;
&#xD;
         10. PR (PQ) interval shortening &lt; 110 ms or evidence of ventricular pre-excitation).&#xD;
&#xD;
         11. PR (PQ) interval prolongation &gt; 240 ms, intermittent second (Wenckebach block while&#xD;
             asleep is not exclusive) or third degree AV block.&#xD;
&#xD;
         12. Persistent or intermittent complete bundle branch block with QRS &gt; 120 ms or evidence&#xD;
             of pronounced ventricular hypertrophy or pre-excitation.&#xD;
&#xD;
         13. Any positive result on screening for serum hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C antibody and human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
         14. Known or suspected history of drug abuse, as judged by the investigator.&#xD;
&#xD;
         15. Current smokers or those who have smoked or used nicotine products within the 3 months&#xD;
             prior to screening.&#xD;
&#xD;
         16. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol, as&#xD;
             judged by the investigator.&#xD;
&#xD;
         17. Positive screen for drugs of abuse, alcohol or cotinine at screening or on each&#xD;
             admission to the unit.&#xD;
&#xD;
         18. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as&#xD;
             judged by the investigator or history of hypersensitivity to drugs with a similar&#xD;
             chemical structure or class to AZD9496.&#xD;
&#xD;
         19. Excessive intake of caffeine/xanthine containing drinks or food (e.g., coffee, tea,&#xD;
             chocolate), as judged by the investigator.&#xD;
&#xD;
         20. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks&#xD;
             prior to the first administration of IMP.&#xD;
&#xD;
         21. Use of any prescribed or non-prescribed medication including antacids, analgesics&#xD;
             (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of&#xD;
             20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to&#xD;
             the first administration of IMP or longer if the medication has a long half-life Note:&#xD;
             Hormonal replacement therapy is not allowed for females.&#xD;
&#xD;
         22. Plasma donation within 1 month of screening or any blood donation/loss more than 500&#xD;
             mL during the 3 months prior to screening&#xD;
&#xD;
         23. Has received another new chemical entity (defined as a compound which has not been&#xD;
             approved for marketing) within 3 months of the first administration of IMP in this&#xD;
             study. The period of exclusion is 3 months after the final dose from previous study or&#xD;
             1 month after the last visit of previous study, whichever is the longest. ote:&#xD;
             Subjects consented and screened, but not dosed in this study or a previous phase I&#xD;
             study, are not excluded.&#xD;
&#xD;
         24. Involvement of any AstraZeneca, PAREXEL or study site employee or their close&#xD;
             relatives&#xD;
&#xD;
         25. Judgment by the investigator that the subject should not participate in the study if&#xD;
             they have any ongoing or recent (i.e., during the screening period) minor medical&#xD;
             complaints that may interfere with the interpretation of study data or are considered&#xD;
             unlikely to comply with study procedures, restrictions and requirements.&#xD;
&#xD;
         26. Subjects who are vegans or have medical dietary restrictions.&#xD;
&#xD;
         27. Subjects who cannot communicate reliably with the investigator.&#xD;
&#xD;
         28. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship,&#xD;
             trusteeship, or committed to an institution by governmental or juridical order.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Ronald Goldwater</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <results_first_submitted>June 6, 2017</results_first_submitted>
  <results_first_submitted_qc>August 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2021</results_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>AZD9496</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>At the United States (US, 1 site), 14 healthy participants were treated with AZD9496 (1 dose at fasted state) in 5 treatment periods: Formulation Variants A, B &amp; C (doses 1,3, &amp; 4), reference (dose 2) and formulation Variant B (dose 5). Each subject was involved in the study for approximately 10 to 12 weeks.</recruitment_details>
      <pre_assignment_details>A screening period of maximum of -28 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Period 1</title>
          <description>Participants received AZD9496 - Variant A (100 mg).</description>
        </group>
        <group group_id="P2">
          <title>Treatment Period 2</title>
          <description>Participants received AZD9496 - Reference (100 mg).</description>
        </group>
        <group group_id="P3">
          <title>Treatment Period 3</title>
          <description>Participants received AZD9496 - Variant B (100 mg).</description>
        </group>
        <group group_id="P4">
          <title>Treatment Period 4</title>
          <description>Participants received AZD9496 - Variant C (100 mg).</description>
        </group>
        <group group_id="P5">
          <title>Treatment Period 5</title>
          <description>Participants received AZD9496 - Variant B (300 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Variant A (100mg)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14">After washout period participants entered Treatment Period 2.</participants>
                <participants group_id="P2" count="0">After washout period participants entered Treatment Period 3.</participants>
                <participants group_id="P3" count="0">After washout period participants entered Treatment Period 4.</participants>
                <participants group_id="P4" count="0">After washout period participants entered Treatment Period 5.</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: Reference (100mg)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3: Variant B (100mg)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4: Variant C (100mg)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5: Variant B (300mg)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All enrolled participants who received at least one dose of AZD9496.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites at Each Treatment Period.</title>
        <description>To evaluate maximum observed plasma concentration (Cmax) for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.</description>
        <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites at Each Treatment Period.</title>
          <description>To evaluate maximum observed plasma concentration (Cmax) for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.</description>
          <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.85" spread="73.54"/>
                    <measurement group_id="O2" value="381.0" spread="55.83"/>
                    <measurement group_id="O3" value="138.2" spread="75.35"/>
                    <measurement group_id="O4" value="91.83" spread="52.13"/>
                    <measurement group_id="O5" value="550.9" spread="41.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" spread="98.93"/>
                    <measurement group_id="O2" value="62.98" spread="76.91"/>
                    <measurement group_id="O3" value="23.56" spread="74.30"/>
                    <measurement group_id="O4" value="14.47" spread="39.01"/>
                    <measurement group_id="O5" value="98.72" spread="54.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.102" spread="85.27"/>
                    <measurement group_id="O2" value="7.409" spread="75.18"/>
                    <measurement group_id="O3" value="2.454" spread="80.35"/>
                    <measurement group_id="O4" value="1.520" spread="42.67"/>
                    <measurement group_id="O5" value="11.71" spread="49.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Curve From Time Zero to Time With Last Observation (AUC0-t) for AZD9496 and Its Metabolites at Each Treatment Period</title>
        <description>To evaluate the area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUC (0-t) of AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation</description>
        <time_frame>Regular Pharmacokinetic measurement: At Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Curve From Time Zero to Time With Last Observation (AUC0-t) for AZD9496 and Its Metabolites at Each Treatment Period</title>
          <description>To evaluate the area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUC (0-t) of AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation</description>
          <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383.4" spread="60.54"/>
                    <measurement group_id="O2" value="1207" spread="53.01"/>
                    <measurement group_id="O3" value="677.8" spread="50.08"/>
                    <measurement group_id="O4" value="523.0" spread="26.77"/>
                    <measurement group_id="O5" value="2322" spread="32.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.71" spread="124.65"/>
                    <measurement group_id="O2" value="196.6" spread="80.92"/>
                    <measurement group_id="O3" value="111.7" spread="62.00"/>
                    <measurement group_id="O4" value="78.23" spread="65.96"/>
                    <measurement group_id="O5" value="411.3" spread="57.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.872" spread="98.91"/>
                    <measurement group_id="O2" value="23.11" spread="73.68"/>
                    <measurement group_id="O3" value="11.05" spread="62.20"/>
                    <measurement group_id="O4" value="7.614" spread="57.93"/>
                    <measurement group_id="O5" value="46.42" spread="49.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Plasma Concentration (Cmax) for Variant A, B and C of AZD9496 Compared to the AZD9496 Reference</title>
        <description>To evaluate maximum plasma concentration (Cmax) of capsule variants by comparing with reference AZD9496</description>
        <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable.</population>
        <group_list>
          <group group_id="O1">
            <title>DN Ratio - Variant A (100 mg): Ref (100 mg)</title>
            <description>Participants received AZD9496 - Variant A (100 mg) in Treatment Period 1.</description>
          </group>
          <group group_id="O2">
            <title>DN Ratio - Variant B (100 mg) : Ref (100 mg)</title>
            <description>Participants received AZD9496 - Variant B (100 mg) in Treatment Period 3.</description>
          </group>
          <group group_id="O3">
            <title>DN Ratio - Variant C (100 mg) : Ref (100 mg)</title>
            <description>Participants received AZD9496 - Variant C (100 mg) in Treatment 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Plasma Concentration (Cmax) for Variant A, B and C of AZD9496 Compared to the AZD9496 Reference</title>
          <description>To evaluate maximum plasma concentration (Cmax) of capsule variants by comparing with reference AZD9496</description>
          <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1702" spread="90.94"/>
                    <measurement group_id="O2" value="0.3440" spread="110.40"/>
                    <measurement group_id="O3" value="0.2285" spread="89.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>17.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.79</ci_lower_limit>
            <ci_upper_limit>24.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>36.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.84</ci_lower_limit>
            <ci_upper_limit>55.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>24.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.84</ci_lower_limit>
            <ci_upper_limit>34.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Curve From Time Zero to Time With Last Observation (AUC0-t) for Variant A, B and C of AZD9496 Compared to the AZD9496 Reference</title>
        <description>To evaluate area under curve from time zero to time with last observation (AUC0-t) of variants by comparing with reference AZD9496</description>
        <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable.</population>
        <group_list>
          <group group_id="O1">
            <title>DN Ratio - Variant A (100 mg): Ref (100 mg)</title>
            <description>Participants received AZD9496 - Variant A (100 mg) in Treatment Period 1.</description>
          </group>
          <group group_id="O2">
            <title>DN Ratio - Variant B (100 mg) : Ref (100 mg)</title>
            <description>Participants received AZD9496 - Variant B (100 mg) in Treatment Period 3.</description>
          </group>
          <group group_id="O3">
            <title>AZD9496 - Variant C (100 mg)</title>
            <description>Participants received this treatment in Treatment Period 4</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Curve From Time Zero to Time With Last Observation (AUC0-t) for Variant A, B and C of AZD9496 Compared to the AZD9496 Reference</title>
          <description>To evaluate area under curve from time zero to time with last observation (AUC0-t) of variants by comparing with reference AZD9496</description>
          <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3175" spread="46.35"/>
                    <measurement group_id="O2" value="0.5227" spread="50.95"/>
                    <measurement group_id="O3" value="0.4033" spread="33.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>31.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.77</ci_lower_limit>
            <ci_upper_limit>39.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>54.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.16</ci_lower_limit>
            <ci_upper_limit>69.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Pecentage</param_type>
            <param_value>41.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.79</ci_lower_limit>
            <ci_upper_limit>48.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for AZD9496 and Its Metabolites at Each Treatment Period.</title>
        <description>To evaluate time to reach maximum observed plasma concentration (Tmax) for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters for AZD9496 could be calculated for at least Treatment Period 2 and 1 other treatment period, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for AZD9496 and Its Metabolites at Each Treatment Period.</title>
          <description>To evaluate time to reach maximum observed plasma concentration (Tmax) for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters for AZD9496 could be calculated for at least Treatment Period 2 and 1 other treatment period, and who had no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="1.50" upper_limit="5.60"/>
                    <measurement group_id="O2" value="2.25" lower_limit="1.50" upper_limit="3.48"/>
                    <measurement group_id="O3" value="3.52" lower_limit="2.50" upper_limit="5.03"/>
                    <measurement group_id="O4" value="4.25" lower_limit="2.50" upper_limit="5.02"/>
                    <measurement group_id="O5" value="4.25" lower_limit="2.50" upper_limit="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" lower_limit="2.00" upper_limit="5.60"/>
                    <measurement group_id="O2" value="2.50" lower_limit="1.50" upper_limit="4.67"/>
                    <measurement group_id="O3" value="3.77" lower_limit="2.98" upper_limit="6.02"/>
                    <measurement group_id="O4" value="5.00" lower_limit="3.00" upper_limit="5.12"/>
                    <measurement group_id="O5" value="4.26" lower_limit="2.50" upper_limit="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" lower_limit="2.00" upper_limit="5.60"/>
                    <measurement group_id="O2" value="2.50" lower_limit="1.50" upper_limit="4.05"/>
                    <measurement group_id="O3" value="4.00" lower_limit="2.50" upper_limit="5.50"/>
                    <measurement group_id="O4" value="4.99" lower_limit="3.00" upper_limit="5.12"/>
                    <measurement group_id="O5" value="4.51" lower_limit="2.50" upper_limit="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effective Half-life ( t½,Eff) for AZD9496 and Its Metabolites at Each Treatment Period</title>
        <description>To evaluate effective half-life (t½,eff), for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.</description>
        <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters for AZD9496 could be calculated for at least Treatment Period 2 and 1 other treatment period, and who had no major protocol deviations thought to impact on the analysis of the PK data. Data not available for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Half-life ( t½,Eff) for AZD9496 and Its Metabolites at Each Treatment Period</title>
          <description>To evaluate effective half-life (t½,eff), for AZD9496 and its metabolites M3 and M5 following administration of different AZD9496 formulations and compare with a reference formulation.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters for AZD9496 could be calculated for at least Treatment Period 2 and 1 other treatment period, and who had no major protocol deviations thought to impact on the analysis of the PK data. Data not available for all participants.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.45"/>
                    <measurement group_id="O2" value="1.11" spread="0.15"/>
                    <measurement group_id="O3" value="1.51" spread="0.68"/>
                    <measurement group_id="O4" value="1.56" spread="0.36"/>
                    <measurement group_id="O5" value="1.36" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.36"/>
                    <measurement group_id="O2" value="1.09" spread="0.17"/>
                    <measurement group_id="O3" value="2.02" spread="1.84"/>
                    <measurement group_id="O4" value="1.57" spread="0.47"/>
                    <measurement group_id="O5" value="1.28" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.27"/>
                    <measurement group_id="O2" value="1.06" spread="0.15"/>
                    <measurement group_id="O3" value="1.54" spread="0.70"/>
                    <measurement group_id="O4" value="1.42" spread="0.36"/>
                    <measurement group_id="O5" value="1.23" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolite to Parent Ratios (MRAUC0-t, MRCmax, MRAUC) at Each Treatment Period.</title>
        <description>To evaluate metabolite to parent ratios (MRAUC0-t, MRCmax, MRAUC) at each treatment period.</description>
        <time_frame>Regular Pharmacokinetic measurement Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters for AZD9496 could be calculated for at least Treatment Period 2 and 1 other treatment period, and who had no major protocol deviations thought to impact on the analysis of the PK data. Data not available for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolite to Parent Ratios (MRAUC0-t, MRCmax, MRAUC) at Each Treatment Period.</title>
          <description>To evaluate metabolite to parent ratios (MRAUC0-t, MRCmax, MRAUC) at each treatment period.</description>
          <population>The PK analysis set consisted of all subjects in the safety analysis set for whom at least 1 of the primary PK parameters for AZD9496 could be calculated for at least Treatment Period 2 and 1 other treatment period, and who had no major protocol deviations thought to impact on the analysis of the PK data. Data not available for all participants.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M3 - MRAUC(0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" spread="48.12"/>
                    <measurement group_id="O2" value="0.163" spread="30.75"/>
                    <measurement group_id="O3" value="0.165" spread="33.49"/>
                    <measurement group_id="O4" value="0.150" spread="41.38"/>
                    <measurement group_id="O5" value="0.177" spread="30.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5 - MRAUC(0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013" spread="33.81"/>
                    <measurement group_id="O2" value="0.019" spread="22.07"/>
                    <measurement group_id="O3" value="0.016" spread="23.06"/>
                    <measurement group_id="O4" value="0.015" spread="32.71"/>
                    <measurement group_id="O5" value="0.020" spread="21.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3 - MRCmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.159" spread="37.68"/>
                    <measurement group_id="O2" value="0.165" spread="25.97"/>
                    <measurement group_id="O3" value="0.170" spread="30.68"/>
                    <measurement group_id="O4" value="0.158" spread="36.29"/>
                    <measurement group_id="O5" value="0.179" spread="27.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5 - MRCmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.017" spread="30.16"/>
                    <measurement group_id="O2" value="0.019" spread="21.01"/>
                    <measurement group_id="O3" value="0.018" spread="31.23"/>
                    <measurement group_id="O4" value="0.017" spread="33.79"/>
                    <measurement group_id="O5" value="0.022" spread="20.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3 - MRAUC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.173" spread="21.11"/>
                    <measurement group_id="O3" value="0.172" spread="7.81"/>
                    <measurement group_id="O5" value="0.193" spread="39.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5 - MRAUC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.020" spread="14.91"/>
                    <measurement group_id="O3" value="0.018" spread="10.90"/>
                    <measurement group_id="O5" value="0.021" spread="26.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Curve From Time Zero to Infinity for Variant A, B and C of AZD9496 Compared to the AZD9496 Reference</title>
        <description>To evaluate area under the curve from time zero to time infinity (AUC 0-infinity) of variants by comparing with reference AZD9496</description>
        <time_frame>Regular Pharmacokinnetic measurement Pre-dose, 0.5, 1, 1.5, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24, and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable. Data not available for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Curve From Time Zero to Infinity for Variant A, B and C of AZD9496 Compared to the AZD9496 Reference</title>
          <description>To evaluate area under the curve from time zero to time infinity (AUC 0-infinity) of variants by comparing with reference AZD9496</description>
          <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable. Data not available for all participants.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data for n=1 available.</measurement>
                    <measurement group_id="O2" value="0.6186" spread="37.26"/>
                    <measurement group_id="O3" value="0.4055" spread="48.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Curve From Time Zero to Infinity (AUC 0-infinity) for AZD9496 and Metabolites at Each Treatment Period</title>
        <description>To evaluate area under the curve from time zero to infinity (AUC 0-infinity) for AZD9496 and its metabolites</description>
        <time_frame>Regular pharmacokinetic measurement pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable. Data not available for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Curve From Time Zero to Infinity (AUC 0-infinity) for AZD9496 and Metabolites at Each Treatment Period</title>
          <description>To evaluate area under the curve from time zero to infinity (AUC 0-infinity) for AZD9496 and its metabolites</description>
          <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable. Data not available for all participants.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data could not be calculated due to n=1.</measurement>
                    <measurement group_id="O2" value="1238" spread="46.88"/>
                    <measurement group_id="O3" value="968.1" spread="30.12"/>
                    <measurement group_id="O4" value="604.7" spread="18.37"/>
                    <measurement group_id="O5" value="2790" spread="22.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="253.2" spread="58.97"/>
                    <measurement group_id="O3" value="99.9" spread="64.10"/>
                    <measurement group_id="O4" value="56.9" spread="30.78"/>
                    <measurement group_id="O5" value="420.6" spread="76.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="95.53"/>
                    <measurement group_id="O2" value="24.09" spread="76.00"/>
                    <measurement group_id="O3" value="11.15" spread="65.47"/>
                    <measurement group_id="O5" value="54.84" spread="47.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: AUC From Time Zero to 12 and 24 Hours Post-dose for AZD9496 and Its Metabolites at Each Treatment Period</title>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable. Data not available for all participants. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: AUC From Time Zero to 12 and 24 Hours Post-dose for AZD9496 and Its Metabolites at Each Treatment Period</title>
          <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable. Data not available for all participants. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496 AUC 0-12 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.2" spread="65.67"/>
                    <measurement group_id="O2" value="1194" spread="51.83"/>
                    <measurement group_id="O3" value="515.3" spread="57.4"/>
                    <measurement group_id="O4" value="326.3" spread="36.18"/>
                    <measurement group_id="O5" value="1920" spread="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AZD9496 AUC 0-24 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.9" spread="60.13"/>
                    <measurement group_id="O2" value="1306" spread="44.9"/>
                    <measurement group_id="O3" value="614.8" spread="49.08"/>
                    <measurement group_id="O4" value="411.7" spread="28"/>
                    <measurement group_id="O5" value="2130" spread="36.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3 AUC 0-12 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.02" spread="72.17"/>
                    <measurement group_id="O2" value="377.3" spread="23.86"/>
                    <measurement group_id="O3" value="91.52" spread="57.32"/>
                    <measurement group_id="O4" value="62.41" spread="33.9"/>
                    <measurement group_id="O5" value="391.6" spread="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3 AUC 0-24 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.26" spread="71.57"/>
                    <measurement group_id="O2" value="NA" spread="NA">Not calculated as n=1.</measurement>
                    <measurement group_id="O3" value="114.9" spread="47.43"/>
                    <measurement group_id="O4" value="91.49" spread="32.74"/>
                    <measurement group_id="O5" value="490.4" spread="47.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5 AUC 0-12 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.162" spread="78.95"/>
                    <measurement group_id="O2" value="37.83" spread="33.76"/>
                    <measurement group_id="O3" value="8.646" spread="74.31"/>
                    <measurement group_id="O4" value="5.953" spread="31.78"/>
                    <measurement group_id="O5" value="40.2" spread="49.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5 AUC 0-24 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.417" spread="65.09"/>
                    <measurement group_id="O2" value="NA" spread="NA">Not calculated as n=1.</measurement>
                    <measurement group_id="O3" value="10.09" spread="60.5"/>
                    <measurement group_id="O4" value="8.32" spread="27.76"/>
                    <measurement group_id="O5" value="46.57" spread="49.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: The Terminal Elimination Half-life (t½,λz) for AZD9496 and Its Metabolites at Each Treatment Period</title>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, hours post-dose on Day 1, 24 and 36 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4) of each treatment period</time_frame>
        <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable. Data not available for all participants. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: The Terminal Elimination Half-life (t½,λz) for AZD9496 and Its Metabolites at Each Treatment Period</title>
          <population>Safety set with 1 primary PK parameter for AZD9496 calculable for Treatment Period 2 and 1 other period. For AUC 0-inf, a predefined R2adj &gt;0.8 (the goodness of fit parameter for regression estimate of elimination rate constant lambda z used in the AUC 0-inf calculation) was used to determine if the individual AUC estimate was reportable. Data not available for all participants. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Not calculated as n=1.</measurement>
                    <measurement group_id="O2" value="2.59" spread="1.75"/>
                    <measurement group_id="O3" value="8.95" spread="7.55"/>
                    <measurement group_id="O4" value="15.66" spread="4.47"/>
                    <measurement group_id="O5" value="9.65" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Not calculated as n=2.</measurement>
                    <measurement group_id="O2" value="1.34" spread="0.39"/>
                    <measurement group_id="O3" value="2.19" spread="2.13"/>
                    <measurement group_id="O4" value="1.89" spread="0.57"/>
                    <measurement group_id="O5" value="3.69" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.47"/>
                    <measurement group_id="O2" value="1.89" spread="1.35"/>
                    <measurement group_id="O3" value="1.41" spread="0.55"/>
                    <measurement group_id="O5" value="5.06" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Apparent Volume of Distribution (Vss/F) of AZD9496 and Its Metabolites at Each Treatment Period</title>
        <time_frame>Day 1, Day 2, Day 3 and Day 4</time_frame>
        <population>Too few data points available. Data not calculated for Vss/F for M3 and M5 .</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Apparent Volume of Distribution (Vss/F) of AZD9496 and Its Metabolites at Each Treatment Period</title>
          <population>Too few data points available. Data not calculated for Vss/F for M3 and M5 .</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="277.5" spread="127.3"/>
                    <measurement group_id="O3" value="1291" spread="1097"/>
                    <measurement group_id="O4" value="3495" spread="1532"/>
                    <measurement group_id="O5" value="920.7" spread="392.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>M5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Apparent Oral Clearance (CL/F) of AZD9496 and Its Metabolites at Each Treatment Period</title>
        <time_frame>Day 1, Day 2, Day 3 and Day 4</time_frame>
        <population>Too few data points available. CL/F not calculated for M3 and M5. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Apparent Oral Clearance (CL/F) of AZD9496 and Its Metabolites at Each Treatment Period</title>
          <population>Too few data points available. CL/F not calculated for M3 and M5. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Not calculated as n=1.</measurement>
                    <measurement group_id="O2" value="80.8" spread="39.8"/>
                    <measurement group_id="O3" value="107.0" spread="32.7"/>
                    <measurement group_id="O4" value="167.5" spread="30.1"/>
                    <measurement group_id="O5" value="110.0" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>M5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Apparent Terminal Elimination Rate Constant (λz) of AZD9496 and Its Metabolites at Each Treatment Period</title>
        <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
        <population>Too few data points available and so λz not calculated for all participants. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Apparent Terminal Elimination Rate Constant (λz) of AZD9496 and Its Metabolites at Each Treatment Period</title>
          <population>Too few data points available and so λz not calculated for all participants. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
          <units>T-1</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Not calculated as n=1.</measurement>
                    <measurement group_id="O2" value="0.3132" spread="58.96"/>
                    <measurement group_id="O3" value="0.1236" spread="183.17"/>
                    <measurement group_id="O4" value="0.0459" spread="31.05"/>
                    <measurement group_id="O5" value="0.0777" spread="46.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Not calculated as n=2.</measurement>
                    <measurement group_id="O2" value="0.537" spread="29.69"/>
                    <measurement group_id="O3" value="0.422" spread="88.14"/>
                    <measurement group_id="O4" value="0.380" spread="34.17"/>
                    <measurement group_id="O5" value="0.230" spread="75.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.618" spread="38.36"/>
                    <measurement group_id="O2" value="0.426" spread="55.48"/>
                    <measurement group_id="O3" value="0.526" spread="41.77"/>
                    <measurement group_id="O5" value="0.154" spread="65.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Mean Residence Time (MRT) of AZD9496 and Its Metabolites at Each Treatment Period</title>
        <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
        <population>Data points not available for all participants. MRT not calculated for M3 and M5 metabolites. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 1</title>
            <description>Participants received AZD9496 - Variant A (100 mg).</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2</title>
            <description>Participants received AZD9496 - Reference (100 mg).</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period 3</title>
            <description>Participants received AZD9496 - Variant B (100 mg).</description>
          </group>
          <group group_id="O4">
            <title>Treatment Period 4</title>
            <description>Participants received AZD9496 - Variant C (100 mg).</description>
          </group>
          <group group_id="O5">
            <title>Treatment Period 5</title>
            <description>Participants received AZD9496 - Variant B (300 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Mean Residence Time (MRT) of AZD9496 and Its Metabolites at Each Treatment Period</title>
          <population>Data points not available for all participants. MRT not calculated for M3 and M5 metabolites. Where less than 3 participants contribute data, the PK parameter was not calculated.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AZD9496</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Not calculated as n=1.</measurement>
                    <measurement group_id="O2" value="3.122" spread="23.77"/>
                    <measurement group_id="O3" value="8.992" spread="107.76"/>
                    <measurement group_id="O4" value="19.73" spread="52.63"/>
                    <measurement group_id="O5" value="7.939" spread="29.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>M5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment until the final follow-up visit (5 to 7 days after last dose)</time_frame>
      <desc>Serious adverse events (SAEs) were recorded from the signing of the informed consent and adverse events (AEs) were recorded from enrollment until the final follow-up visit.&#xD;
Note: A total of 4 participants reported at least one AE. Of the 4 participants, 1 participant reported two AEs &quot;Rhinorrhoea&quot; and &quot;Body tinea&quot; associated with treatments Variant A and B, respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Period 1</title>
          <description>Participants received AZD9496 - Variant A (100 mg).</description>
        </group>
        <group group_id="E2">
          <title>Treatment Period 2</title>
          <description>Participants received AZD9496 - Reference (100 mg).</description>
        </group>
        <group group_id="E3">
          <title>Treatment Period 3</title>
          <description>Participants received AZD9496 - Variant B (100 mg).</description>
        </group>
        <group group_id="E4">
          <title>Treatment Period 4</title>
          <description>Participants received AZD9496 - Variant C (100 mg).</description>
        </group>
        <group group_id="E5">
          <title>Treatment Period 5</title>
          <description>Participants received AZD9496 - Variant B (300 mg).</description>
        </group>
        <group group_id="E6">
          <title>All Participants</title>
          <description>All enrolled participants who received at least one dose of AZD9496.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <description>Note: Participant who reported &quot;Rhinorrhoea&quot; also reported &quot;Body tinea&quot;</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <description>Note: Participant who reported &quot;Body tinea&quot; also reported &quot;Rhinorrhoea&quot;</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All of the study information and data collected during the study are confidential and the property of AstraZeneca. After completion of the study, the investigator may prepare a joint publication with AstraZeneca. The investigator must undertake not to submit any part of the individual data from this clinical study protocol for publication without prior consent of AstraZeneca at a mutually agreed time.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data from all analysed secondary pharmacokinetic parameters are presented.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>AZD9496 Global clinical leader</name_or_title>
      <organization>AstraZeneca AB</organization>
      <phone>+46317761000</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

